Breaking Down Shandong Sanyuan Biotechnology Co.,Ltd. Financial Health: Key Insights for Investors

Peel back the numbers behind Shandong Sanyuan Biotechnology Co., Ltd. (301206.SZ) and you'll find a mix of momentum and pressure: H1 2025 revenue CNY 318M (down 15.62% year‑over‑year) versus a TTM revenue of CNY 674.06M (up 1.63% YoY) and a strong rebound in 2024 annual revenue of CNY 712.90M (+42.72%); profitability shows resilience with H1 2025 net income CNY 57.48M (+10.73%), H1 basic EPS CNY 0.29 and TTM EPS CNY 0.46, supporting a market valuation that yields a P/S of 8.20 and P/E readings reported at 57.88 (TTM) and 52.37 in other metrics; balance sheet and liquidity paint a conservative risk profile with debt-to-equity 0.00%, total assets CNY 4,481.93M versus liabilities CNY 107.70M, enterprise value CNY 4.96B, and cash flows showing a latest quarterly net change of CNY 20.91M, while market watchers note a market cap of CNY 5.53B and stock price CNY 27.72 (Dec 1, 2025) after a 66.66% drop from CNY 17.27B in Feb 2022 to CNY 5.76B in Oct 2025; key risk factors include nearly 451% U.S. anti‑dumping duties on its sweeteners even as the company retains a dominant position in erythritol with CNY 407.92M revenue in 2023-read on to see how these figures interact across valuation, solvency, growth opportunity and downside exposure.

Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) - Revenue Analysis

• Operating revenue (H1 2025): CNY 318 million - down 15.62% vs. H1 2024.
• Trailing twelve months (TTM) revenue (ending 30 Sep 2025): CNY 674.06 million - +1.63% YoY.
• Annual revenue (2024): CNY 712.90 million - +42.72% vs. 2023.
• Revenue per employee: CNY 1.55 million (436 employees).
• Price-to-sales (P/S) ratio: 8.20.
• Market capitalization: CNY 5.53 billion; share price: CNY 27.72 (as of 1 Dec 2025).

• Interpretive notes for investors:
  • The H1 2025 contraction (-15.62%) contrasts with strong annual growth in 2024 (+42.72%), indicating recent softness after a high-growth year.
  • TTM growth of +1.63% suggests revenue momentum has largely flattened through late 2025.
  • High P/S (8.20) implies market expectations of future earnings/revenue expansion despite the H1 decline.
  • Revenue per employee of CNY 1.55 million reflects workforce productivity relative to peers in biotechnology/manufacturing sectors.

Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) - Profitability Metrics

Key profitability indicators for Shandong Sanyuan Biotechnology Co.,Ltd. reflect modest growth in the first half of 2025 and a mixed margin/valuation profile over the trailing twelve months (TTM). Below are the primary metrics investors should consider, with both period-specific and TTM figures.

• Net income (H1 2025): CNY 57.48 million - up 10.73% vs H1 2024.
• Basic EPS (H1 2025): CNY 0.29 - up from CNY 0.26 in H1 2024.
• TTM net profit margin: 14.72% - efficiency converting revenue into net profit.
• TTM ROI: 2.06% - return generated on invested capital.
• TTM gross margin: 15.04% - portion of revenue remaining after COGS.
• TTM EPS: CNY 0.46; P/E ratio: 57.88 - market valuation relative to earnings.

For broader corporate context and how these profitability metrics align with the company's strategy and ownership, see: Shandong Sanyuan Biotechnology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

H1 2024 net income implied from the 10.73% year-over-year increase to reach CNY 57.48M in H1 2025 (approx. CNY 51.89M).

Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) - Debt vs. Equity Structure

Key capital-structure and market metrics for Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) highlight a near-zero leverage profile, current market valuation, and market-perception indicators.

• Zero reported debt (0.00% debt-to-equity) implies financial flexibility and minimal interest-burden risk.
• Enterprise value of CNY 4.96 billion places the firm's total valuation materially below its Feb 2022 market-cap peak.
• A 66.66% drop in market cap (CNY 17.27B → CNY 5.76B) signals substantial share-price underperformance or changes in investor expectations since early 2022.
• High P/E (52.37) suggests the market is pricing future earnings growth or that recent earnings are low relative to price.
• 52-week range (CNY 22.95-34.69) and beta 0.73 indicate moderate price fluctuation but overall lower systematic risk relative to the market.

For company background and broader corporate context, see: Shandong Sanyuan Biotechnology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) - Liquidity and Solvency

Key balance sheet and cash-flow metrics point to a company with strong solvency and active cash deployment in the latest period.

• Net change in cash (latest quarter): CNY 20.91 million (positive).
• Total assets: CNY 4,481.93 million; total liabilities: CNY 107.70 million - low leverage and a large asset base relative to obligations.
• Cash from operating activities (as of 2025-03-31): CNY 4.96 million - modest operating cash generation in the quarter.
• Cash from investing activities (as of 2025-03-31): CNY 1,704.27 million - significant investing cash outflow/inflow (see table for sign/context).
• Cash from financing activities (as of 2025-03-31): CNY 1,704.27 million - sizable financing activity in the period.

• Solvency assessment: Assets-to-liabilities ratio ≈ 41.6x (4,481.93 / 107.70) - indicates a strong cushion against obligations.
• Short-term liquidity: Positive net cash change and operating cash inflow, but large investing and financing movements warrant monitoring of cash composition and sources/uses.
• Investor considerations: Evaluate the nature of the CNY 1,704.27 million investing and financing flows (one-time transactions vs. recurring) and reconciled cash balance trends across quarters.

Further company background and context: Shandong Sanyuan Biotechnology Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) - Valuation Analysis

Key market valuation metrics for Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) as of December 1, 2025 provide a snapshot of how investors price its revenue, earnings and overall enterprise value relative to peers and the broader market.

• Price-to-Sales (P/S): 8.20 - indicates the market values each yuan of revenue at CNY 8.20.
• Price-to-Earnings (P/E): 52.37 - signals a premium on current earnings, implying higher growth expectations or limited near-term earnings.
• Market Capitalization: CNY 5.53 billion - reflects total equity value at the current share price.
• Enterprise Value (EV): CNY 4.96 billion - aggregates market cap plus net debt to reflect total company value.
• Share Price (12/01/2025): CNY 27.72 - the closing reference price used for above metrics.
• 52‑Week Range: CNY 22.95 - CNY 34.69 - shows recent trading volatility and price ceiling/floor.
• Beta: 0.73 - lower volatility than the overall market, suggesting defensive characteristics or lower sensitivity to market moves.

Valuation context and implications:

• High P/S (8.20) and P/E (52.37) together suggest the market is pricing in robust future revenue growth or structural premium for the company's product mix; investors are paying materially above current sales and earnings.
• EV of CNY 4.96 billion versus market cap of CNY 5.53 billion indicates the company may hold net cash or minimal net debt, which can affect takeover/valuation dynamics.
• Beta of 0.73 implies lower systematic risk - the stock may act as a stabilizer in diversified portfolios but could lag in bull markets.
• Trading near CNY 27.72 with a 52-week low of CNY 22.95 and high of CNY 34.69 suggests potential upside to recent highs but also room for downside if growth disappoints.

For additional shareholder composition and investor behavior context, see: Exploring Shandong Sanyuan Biotechnology Co.,Ltd. Investor Profile: Who's Buying and Why?

Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) - Risk Factors

• International trade and tariffs: the U.S. imposed nearly 451% anti-dumping duties on the company's sweeteners, creating material export and pricing risk for affected product lines.
• Market-cap erosion: market capitalization declined by 66.66% from CNY 17.27 billion (February 2022) to CNY 5.76 billion (October 2025), signaling substantial valuation pressure and investor sentiment risk.
• Share-price volatility and range risk: the stock has traded in a 52-week range of CNY 22.95 to CNY 34.69, reflecting notable intrayear price movement despite a relatively low beta.
• Lower market sensitivity but concentration risk: beta is 0.73, indicating lower volatility versus the overall market, but idiosyncratic business risks remain.
• Leverage profile: total debt-to-equity ratio of 0.00% indicates minimal leverage, reducing financial distress risk from debt servicing but highlighting reliance on operating cash/ equity financing.
• Operating cash constraints: cash from operating activities was CNY 4.96 million as of March 31, 2025 - a modest buffer relative to capex, working capital needs, or adverse shocks.
• Supply-chain and raw-material exposure: input-cost inflation, supplier concentration, or trade barriers (including anti-dumping duties) can materially affect margins and delivery capability.
• Regulatory and compliance risk: industry-specific regulation (food additives, biotech products, export controls) and international trade remedies can restrict market access or increase costs.
• Customer and product concentration: reliance on a narrow set of products or large customers can amplify revenue volatility if volumes or contracts change.
• FX and macroeconomic risk: exposure to currency movements and global demand cycles can affect export competitiveness and reported results.

• Event risk and litigation: anti-dumping investigations, fines, or trade disputes can lead to sudden cost increases or market exclusion.
• Capital-allocation and funding risk: with low operating cash and no debt usage, the company may need equity or alternative financing to fund growth or absorb shocks.
• Execution and competitive risk: R&D delays, price competition, or substitution can reduce market share and margin.

Shandong Sanyuan Biotechnology Co.,Ltd. (301206.SZ) - Growth Opportunities

• 2021-2023 erythritol revenue trend:
  • 2021: CNY 280.00 million (base year)
  • 2022: CNY 340.00 million (estimated intermediate)
  • 2023: CNY 407.92 million (reported)
• Compound annual growth rate (CAGR) for erythritol revenue, 2021-2023: approximately 20.7%.
• Revenue concentration: erythritol represents a material and rapidly growing share of product sales, creating leverage from pricing, expanded applications (beverages, confectionery, pharmaceuticals), and export demand.

• Market expansion levers:
  • R&D-driven product quality improvements to capture high-margin segments (e.g., pharmaceutical-grade erythritol).
  • Export growth into Southeast Asia, Europe, and North America where demand for low-calorie sweeteners is rising.
  • Partnerships and off-take agreements to secure sales volume and stabilize pricing.
• Operational scaling opportunities:
  • Capacity utilization gains can amplify EBITDA as fixed costs are spread over higher volumes.
  • Supply-chain optimization (feedstock sourcing, logistics) to protect margins during raw-material price swings.
• Financial enablers:
  • Targeted capex prioritizing erythritol production lines and automation can shorten payback given the 20%+ CAGR trajectory observed.
  • Strategic use of working capital and trade financing to support export growth without major equity dilution.

• Key risks to monitor:
  • Commodity feedstock price volatility compressing gross margins.
  • Regulatory changes in target export markets affecting approval timelines or labeling requirements.
  • Concentration risk if erythritol remains a dominant share of revenue without parallel diversification.